Table 1.
Baseline characteristics of total and separate hepatocellular carcinoma groups treated with sorafenib
| Demographics | Total cases (n = 156) | Group I (n = 52) | Group II (n = 58) | Group III (n = 46) |
|---|---|---|---|---|
| Age (yrs) (range) | 61.04 ± 12.76 (32.00–88.00) | 58.75 ± 13.33 (32.0–84.0) | 60.36 ± 12.45 (32.0–88.0) | 64.50 ± 12.02 (40.0–86.0) |
| Sex (Male) (%) | 127 (81.41) | 46 (88.5) | 52 (89.66) | 29 (63.04) |
| BMI (kgs/m2) (range) | 22.69 ± 3.88(14.10–34.82) | 23.05 ± 3.71 (15.24–34.82) | 21.92 ± 3.48 (14.10–32.86) | 23.26 ± 4.43 (15.56–33.75) |
| Cirrhosis (+) (%) | 120 (76.92) | 32 (61.5) | 50 (86.21) | 38 (82.61) |
| CPC, score 5 versus 6 (%) | 81 (51.92) versus 75 (48.08) | 30 (57.7) versus 22 (42.3) | 31 (53.45) versus 27 (46.55) | 20 (43.48) versus 26 (56.52) |
| Biochemical values | ||||
| Albumin (g/dL) (range) | 3.88 ± 0.50 (2.80–5.10) | 4.05 ± 0.42 (3.20–4.80) | 3.88 ± 0.51 (2.80–5.10) | 3.68 ± 0.51 (2.80–4.70) |
| Bilirubin (mg/dL) (range) | 1.02 ± 0.46 (0.19–2.41) | 0.99 ± 0.41 (0.22–1.99) | 1.03 ± 0.48 (0.19–2.29) | 1.05 ± 0.51 (0.38–2.41) |
| INR (range) | 1.14 ± 0.13 (0.89–1.63) | 1.13 ± 0.12 (0.90–1.63) | 1.15 ± 0.13 (0.90–1.48) | 1.15 ± 0.15 (0.89–1.63) |
| AST (IU/L) (range) | 92.45 ± 105.98 (22.00–805.00) | 96.20 ± 102.12 (24.00–580.00) | 95.07 ± 136.90 (22.00–805.00) | 84.84 ± 53.33 (23.00–237.00) |
| ALT (IU/L) (range) | 66.54 ± 102.12 (9.00–1156.00) | 65.73 ± 48.32 (15.00–251.00) | 76.86 ± 157.43 (9.00–1156.00) | 54.43 ± 39.91 (13.00–202.00) |
| ALK-P (IU/L) (range) | 127.76 ± 93.34 (43.00–680.00) | 124.84 ± 81.74 (50.00–421.00) | 113.14 ± 93.05 (45.00–680.00) | 155.0 ± 104.82 (43.00–526.00) |
| AFP (ng/mL) (range) | 9000.31 ± 17472.65 (0.91–54001.0) | 11769.7 ± 19836.59 (1.64–54001.0) | 6663.7 ± 14569.6 (0.91–54001.0) | 8815.86 ± 17910.81 (1.30–54001.0) |
| Cr (mg/dL) (range) | 0.93 ± 0.35 (0.21–2.76) | 0.90 ± 0.30 (0.40–2.10) | 0.94 ± 0.32 (0.27–1.76) | 0.95 ± 0.43 (0.21–2.76) |
| WBC (103/uL) (range) | 6.90 ± 3.71 (1.70–22.62) | 6.96 ± 3.33 (2.48–17.35) | 6.79 ± 3.66 (1.70–19.00) | 7.00 ± 4.23 (2.10–22.62) |
| Hb (gm/dL) (range) | 12.48 ± 1.97 (7.90–17.10) | 12.63 ± 1.98 (7.90–16.00) | 12.64 ± 2.02 (7.90–17.10) | 12.11 ± 1.89 (8.10–15.10) |
| Platelet (103/uL) (range) | 171.49 ± 110.79 (16.00–796.00) | 170.69 ± 82.45 (16.00–400.00) | 177.19 ± 145.22 (44.00–796.0) | 165.2 ± 88.18 (23.00–386.00) |
| Virologic values | ||||
| B or C or B + C (+) or NBNC (%) | 80 (51.28) or 50 (32.05) or 5 (3.21) or 21 (13.46) | 30 (57.7) or 9 (17.3) or 3 (5.8) or 10 (19.2) | 33 (56.9) or 18 (31.03) or 1 (1.72) or 6 (10.34) | 17 (36.96) or 23 (50.0) or 1 (2.17) or 5(10.87) |
| Tumor characters | ||||
| Tumor size (>5 cm) (%) | 74 (47.44) | 27 (51.9) | 25 (43.1) | 22 (47.83) |
| Tumor number (>3) (%) | 91 (58.33) | 28 (53.8) | 32 (55.17) | 31 (67.39) |
| Intra-hepatic vein (+) (%) | 61 (39.10) | 23 (44.2) | 18 (31.03) | 20 (43.48) |
| Extra-hepatic metastases (%) | 75 (48.08) | 23 (44.2) | 31 (53.45) | 21 (45.65) |
| Mixed type (vein and metastases) | 20 (12.82) | 6 (11.5) | 9 (15.52) | 5 (10.87) |
Abbreviations: CPC child-pugh classification, INR international normalize ratio, AST aspartate transaminase, ALT alanine transaminase, Alk-p alkaline phosphatase, GGT gamma-glutamyltransferase, AFP alpha-fetoprotein, Cr creatinine, WBC white blood cell, Hb hemoglobin, B hepatitis B virus, C hepatitis C virus, B + C hepatitis B and C virus, NBNC non-hepatitis B or C virus